Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Recordati SpA
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.
During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Consumers’ saliva, blood or stool samples provide more information but questionnaires are more comfortable, says Nate Matusheski of DSM Nutritional Products business Hologram Sciences. “If you think about the user experience, there's a kind of a big difference in invasiveness across these different categories.”
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Bouchara Recordati
- Dr. F. Frik Ilaç A.S.
- Opalia Pharma S.A.
- Orphan Europe
- Recordati Pharmaceuticals Ltd.
- Laboratorios Casen Fleet
- Italchimici S.p.A.
- Pro Farma AG
- Recordati S.A. Chemical and Pharmaceutical Company
- Recordati Rare Diseases Canada Inc.
- Natural Point S.r.l.
- Tonipharm S.A.S.
- FIMEI S.p.A
- Rossini Investimenti S.p.A